331P A Phase 1/2 clinical trial of the antisense oligonucleotide BMN 351 now actively recruiting boys with exon 51–skip-amenable Duchenne muscular dystrophy
20241 citationsJournal Article
Field-Weighted Citation Impact: 0.24
331P A Phase 1/2 clinical trial of the antisense oligonucleotide BMN 351 now actively recruiting boys with exon 51–skip-amenable Duchenne muscular dystrophy | Researchclopedia